NASDAQ:TSBX Turnstone Biologics (TSBX) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free TSBX Stock Alerts $2.76 -0.14 (-4.83%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.74▼$3.0450-Day Range$2.27▼$5.4852-Week Range$1.63▼$13.20Volume130,089 shsAverage Volume174,521 shsMarket Capitalization$63.84 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Turnstone Biologics alerts: Email Address Turnstone Biologics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside588.4% Upside$19.00 Price TargetShort InterestHealthy4.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.34) to ($3.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsMedical Sector661st out of 913 stocksBiological Products, Except Diagnostic Industry105th out of 145 stocks 3.3 Analyst's Opinion Consensus RatingTurnstone Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTurnstone Biologics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.76% of the float of Turnstone Biologics has been sold short.Short Interest Ratio / Days to CoverTurnstone Biologics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Turnstone Biologics has recently increased by 0.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTurnstone Biologics does not currently pay a dividend.Dividend GrowthTurnstone Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSBX. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 2 people have searched for TSBX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows1 people have added Turnstone Biologics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Turnstone Biologics insiders have not sold or bought any company stock.Percentage Held by Institutions52.51% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Turnstone Biologics are expected to grow in the coming year, from ($3.34) to ($3.22) per share.Price to Book Value per Share RatioTurnstone Biologics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Turnstone Biologics Stock (NASDAQ:TSBX)Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.Read More TSBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSBX Stock News HeadlinesApril 18, 2024 | uk.investing.comTurnstone Biologics announces board member resignationApril 16, 2024 | globenewswire.comTurnstone Biologics Appoints William Waddill to its Board of DirectorsApril 27, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 12, 2024 | seekingalpha.comTSBX Turnstone Biologics Corp.March 22, 2024 | investorplace.comTSBX Stock Earnings: Turnstone Biologics Beats EPS for Q4 2023March 21, 2024 | globenewswire.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business HighlightsMarch 2, 2024 | finance.yahoo.comTurnstone Biologics Corp. (NASDAQ:TSBX) institutional investors have had a good week as stock gains 34%February 23, 2024 | benzinga.comTurnstone Biologics Stock (NASDAQ:TSBX), Short Interest ReportApril 27, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. February 21, 2024 | finance.yahoo.comTurnstone Biologics to Participate in Upcoming Investor ConferencesFebruary 21, 2024 | globenewswire.comTurnstone Biologics to Participate in Upcoming Investor ConferencesFebruary 20, 2024 | finance.yahoo.comTurnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.February 20, 2024 | globenewswire.comTurnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.January 23, 2024 | msn.comRUM, ENVB and GAME among mid-day moversJanuary 21, 2024 | finance.yahoo.comHere's Why Turnstone Biologics (NASDAQ:TSBX) Must Use Its Cash WiselyJanuary 3, 2024 | seekingalpha.comIPOs In 2023 Disappoint But 2024 Looks BrighterNovember 27, 2023 | finance.yahoo.comTurnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare ConferenceNovember 19, 2023 | realmoney.thestreet.comTurnstone Biologics price target lowered to $15 from $18 at BofANovember 10, 2023 | msn.comTurnstone Biologics GAAP EPS of -$1.00November 10, 2023 | msn.comTurnstone Biologics GAAP EPS of $1.00November 9, 2023 | finance.yahoo.comTurnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business HighlightsNovember 5, 2023 | morningstar.comTurnstone Biologics Corp TSBXNovember 3, 2023 | finance.yahoo.comTurnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingSeptember 28, 2023 | finance.yahoo.comTurnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 4, 2023 | msn.comTurnstone Biologics GAAP EPS of -$7.56 misses by $6.82September 1, 2023 | finance.yahoo.comTurnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 28, 2023 | wsj.comTurnstone Biologics Corp.See More Headlines Receive TSBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/26/2024Next Earnings (Estimated)6/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TSBX CUSIPN/A CIK1764974 Webturnstonebio.com Phone347-897-5988FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$20.00 Low Stock Price Target$18.00 Potential Upside/Downside+588.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,200,000.00 Net MarginsN/A Pretax Margin-287.40% Return on EquityN/A Return on Assets-54.02% Debt Debt-to-Equity RatioN/A Current Ratio8.57 Quick Ratio8.57 Sales & Book Value Annual Sales$19.31 million Price / Sales3.31 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book0.65Miscellaneous Outstanding Shares23,130,000Free FloatN/AMarket Cap$63.84 million OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Sammy J. Farah M.B.A. (Age 52)Ph.D., President, CEO & Director Comp: $678.51kDr. Venkat Ramanan Ph.D. (Age 55)Chief Financial Officer Comp: $346.13kDr. Michael F. Burgess M.D. (Age 60)MBChB, Ph.D., Interim Chief Medical Officer & Executive Director Comp: $212.69kMs. Saryah Azmat (Age 35)Chief Business Officer Comp: $479.73kDr. Vijay Chiruvolu M.B.A. (Age 62)Ph.D., Interim Chief Technology Officer Dr. Stewart Abbot Ph.D. (Age 57)Chief Scientific Officer More ExecutivesKey CompetitorsInstil BioNASDAQ:TILPrecision BioSciencesNASDAQ:DTILElutiaNASDAQ:ELUTIkena OncologyNASDAQ:IKNAJATT AcquisitionNYSE:JATTView All CompetitorsInsiders & InstitutionsKathleen S. Wright Associates Inc.Bought 42,553 shares on 4/17/2024Ownership: 0.184%PFM Health Sciences LPSold 891,397 shares on 2/15/2024Ownership: 2.742%Caas Capital Management LPSold 30,677 shares on 2/15/2024Ownership: 0.198%Versant Ventures V, LlcBought 225,000 shares on 7/25/2023Total: $2.70 M ($12.00/share)Rishi GuptaBought 416,666 shares on 7/20/2023Total: $5.00 M ($12.00/share)View All Insider TransactionsView All Institutional Transactions TSBX Stock Analysis - Frequently Asked Questions Should I buy or sell Turnstone Biologics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turnstone Biologics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSBX shares. View TSBX analyst ratings or view top-rated stocks. What is Turnstone Biologics' stock price target for 2024? 4 brokerages have issued 12-month price objectives for Turnstone Biologics' shares. Their TSBX share price targets range from $18.00 to $20.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 588.4% from the stock's current price. View analysts price targets for TSBX or view top-rated stocks among Wall Street analysts. How have TSBX shares performed in 2024? Turnstone Biologics' stock was trading at $2.55 at the beginning of 2024. Since then, TSBX stock has increased by 8.2% and is now trading at $2.76. View the best growth stocks for 2024 here. Are investors shorting Turnstone Biologics? Turnstone Biologics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 625,900 shares, an increase of 42.9% from the March 15th total of 438,000 shares. Based on an average trading volume of 181,300 shares, the short-interest ratio is currently 3.5 days. Currently, 4.7% of the shares of the company are sold short. View Turnstone Biologics' Short Interest. When is Turnstone Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 20th 2024. View our TSBX earnings forecast. How were Turnstone Biologics' earnings last quarter? Turnstone Biologics Corp. (NASDAQ:TSBX) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.13. When did Turnstone Biologics IPO? Turnstone Biologics (TSBX) raised $80 million in an initial public offering on Friday, July 21st 2023. The company issued 6,666,667 shares at $12.00 per share. Who are Turnstone Biologics' major shareholders? Turnstone Biologics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Kathleen S. Wright Associates Inc. (0.18%). Insiders that own company stock include Rishi Gupta and Versant Ventures V, Llc. View institutional ownership trends. How do I buy shares of Turnstone Biologics? Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSBX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
